Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31 2024 - 4:15PM
Business Wire
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in
precision genetic medicine for rare diseases, granted equity awards
on July 31, 2024 (the “Grant Date”) that were previously approved
by the Compensation Committee of its Board of Directors under
Sarepta’s 2024 Employment Commencement Incentive Plan, as a
material inducement to employment to 19 individuals hired by
Sarepta in July 2024. The equity awards were approved in accordance
with Nasdaq Listing Rule 5635(c)(4).
The employees received in the aggregate 14,495 restricted stock
units (“RSUs”). One-fourth of the RSUs will vest yearly on each
anniversary of the Grant Date, such that the RSUs granted to each
employee will be fully vested on the fourth anniversary of the
Grant Date, in each case, subject to each such employee’s continued
employment with Sarepta on such vesting date. Employees did not
receive options to purchase shares of Sarepta’s common stock.
About Sarepta Therapeutics Sarepta is on an urgent mission:
engineer precision genetic medicine for rare diseases that
devastate lives and cut futures short. We hold leadership positions
in Duchenne muscular dystrophy (DMD) and limb-girdle muscular
dystrophies (LGMDs), and we currently have more than 40 programs in
various stages of development. Our vast pipeline is driven by our
multi-platform Precision Genetic Medicine Engine in gene therapy,
RNA and gene editing. For more information, please visit
www.sarepta.com or follow us on LinkedIn, X (formerly Twitter),
Instagram and Facebook.
Internet Posting of Information We routinely post information
that may be important to investors in the 'For Investors' section
of our website at www.sarepta.com. We encourage investors and
potential investors to consult our website regularly for important
information about us.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240731742607/en/
Investor Contact: Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact: Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Oct 2024 to Nov 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Nov 2023 to Nov 2024